The latest news from academia, regulators
research labs and other things of interest
Posted: February 19, 2008
NanoInk Appoints Ben Pothast Chief Financial Officer
(Nanowerk News) NanoInk, Inc. announced today the appointment of Ben Pothast as its chief financial officer.
"We are thrilled that Ben has joined the NanoInk team," said Jim Hussey, CEO of NanoInk. "Ben brings more than 20 years of diverse financial experience to NanoInk. We believe his excellent track record at some of the world's leading pharmaceutical companies will help drive our future growth."
Mr. Pothast joins NanoInk from Cambridge Major Laboratories, Inc., a privately held service-based chemistry outsourcing partner to the world's leading pharmaceutical and biotechnology companies, where he served as chief financial officer. Mr. Pothast was the first CFO in the company's history and a key member of the management team.
Previously, Mr. Pothast was vice president of planning and analysis at Ovation Pharmaceuticals, Inc., a leading biopharmaceutical company. At Ovation, Mr. Pothast was responsible for all treasury and portfolio management functions. He was a key member of the acquisition team focused on due diligence and debt and equity financing.
Prior to his work at Ovation Pharmaceuticals, Mr. Pothast served as chief financial officer of Akorn, Inc., a publicly traded specialty pharmaceutical company that develops, manufactures and markets ophthalmic and injectable products.
Mr. Pothast began his career at Ernst & Young in Chicago and is a certified public accountant. He holds a B.A. in Accounting and Business Administration from Augustana College and a Masters of Management from the Kellogg Graduate School of Business at Northwestern University.
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN®, a patented and proprietary nanofabrication technology that allows for unmatched flexibility and accuracy, and also its high-resolution Nanoencryption™ technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, the University of Illinois at Urbana-Champaign, and the Georgia Institute of Technology. For more information on products and services offered by NanoInk, Inc., see www.nanoink.net.